UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study

Hypertension (Dallas, Tex. 1979), 2005-02, Vol.45 (2), p.198-202

2005

Volltextzugriff (PDF)

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

Kidney international, 2004-03, Vol.65 (3), p.1041-1049

2004

Volltextzugriff (PDF)

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

Journal of hypertension, 2004-09, Vol.22 (9), p.1805-1811

2004

Volltextzugriff (PDF)

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

Hypertension (Dallas, Tex. 1979), 2005-01, Vol.45 (1), p.46-52

2005

Volltextzugriff (PDF)

The Losartan Intervention For Endpoint Reduction (LIFE) in hypertension study: Rationale, design, and methods

American journal of hypertension, 1997-07, Vol.10 (7), p.705-713

1997

Volltextzugriff (PDF)

Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study

Nutrition, metabolism, and cardiovascular diseases, 2009-06, Vol.19 (5), p.306-312

2009

Volltextzugriff (PDF)

Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy : The LIFE (losartan intervention for endpoint reduction in hypertension) study

Circulation (New York, N.Y.), 2005-04, Vol.111 (15), p.1924-1931

2005

Volltextzugriff (PDF)

Pulse Pressure and Effects of Losartan or Atenolol in Patients With Hypertension and Left Ventricular Hypertrophy

Hypertension (Dallas, Tex. 1979), 2005-04, Vol.45 (4), p.580-585

2005

Volltextzugriff (PDF)

Left Atrial Size and Risk of Major Cardiovascular Events During Antihypertensive Treatment: Losartan Intervention for Endpoint Reduction in Hypertension Trial

Hypertension (Dallas, Tex. 1979), 2007-02, Vol.49 (2), p.311-316

2007

Volltextzugriff (PDF)

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

The Lancet (British edition), 2002-03, Vol.359 (9311), p.995-1003

2002

Volltextzugriff (PDF)

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study

Journal of the American College of Cardiology, 2005-09, Vol.46 (5), p.770

2005

Volltextzugriff (PDF)

Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy

Current medical research and opinion, 2007-02, Vol.23 (2), p.259-270

2007

Volltextzugriff (PDF)

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

The Lancet (British edition), 2002-03, Vol.359 (9311), p.1004-1010

2002

Volltextzugriff (PDF)

Cardiac biochemical markers after cardioversion of atrial fibrillation or atrial flutter

The American heart journal, 2000-10, Vol.140 (4), p.690-696

2000

Volltextzugriff (PDF)

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

Annals of internal medicine, 2003-12, Vol.139 (11), p.901

2003

Volltextzugriff (PDF)

Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

Blood pressure, 2009, Vol.18 (6), p.348-361

2009

Volltextzugriff (PDF)

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

JAMA : the journal of the American Medical Association, 2002-09, Vol.288 (12), p.1491

2002

Volltextzugriff (PDF)

Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension

Journal of hypertension, 1995-11, Vol.13 (11), p.1343-1351

1995

Volltextzugriff (PDF)

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Journal of hypertension, 2002-09, Vol.20 (9), p.1879-1886

2002

Volltextzugriff (PDF)

Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study

American journal of hypertension, 2000-08, Vol.13 (8), p.899-906

2000

Volltextzugriff (PDF)

How smoking affects blood pressure

Blood pressure, 1996, Vol.5 (2), p.71-77

Omvik, Per

1996

Volltextzugriff (PDF)

Reproducibility of salt sensitivity testing using a dietary approach in essential hypertension

Journal of human hypertension, 1999-06, Vol.13 (6), p.375-384

1999

Volltextzugriff (PDF)

Reducing Microalbuminuria-Does It Lower Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005

Journal of the American Society of Nephrology, 2005-09, Vol.16 (9), p.2521-2527

2005

Volltextzugriff (PDF)

Lowering Albuminuria-Does It Lower the Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005

Journal of the American Society of Nephrology, 2005-08, Vol.16 (8), p.2247-2250

2005

Volltextzugriff (PDF)

Magnetic resonance imaging and cine computerized tomography as future tools for cardiac output measurement

European heart journal, 1990-12, Vol.11 (suppl-I), p.141-143

Omvik, P

1990

Volltextzugriff (PDF)

1 – 25 von 175

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(164)
Mit Volltextzugriff
(137)

Publikationsform

Sprache

Englisch
(157)
Norwegisch
(18)

Erscheinungsjahr

n.n

Thema

Humans
(132)
Male
(114)
Middle Aged
(98)
Female
(89)
Hypertension - Drug Therapy
(76)
Life Sciences & Biomedicine
(75)
Science & Technology
(75)
Adult
(74)
Aged
(60)
Biological And Medical Sciences
(59)
Hypertension - Physiopathology
(59)
Medical Sciences
(59)
Hypertension
(56)
Cardiovascular System & Cardiology
(51)
Blood Pressure - Drug Effects
(44)
Antihypertensive Agents - Therapeutic Use
(39)
Hemodynamics - Drug Effects
(39)
Antihypertensive Agents
(35)
Cardiovascular System
(34)
Pharmacology. Drug Treatments
(34)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

The Losartan Intervention For Endpoint Reduction (LIFE) in hypertension study: Rationale, design, and methods

Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study

Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy : The LIFE (losartan intervention for endpoint reduction in hypertension) study

Pulse Pressure and Effects of Losartan or Atenolol in Patients With Hypertension and Left Ventricular Hypertrophy

Left Atrial Size and Risk of Major Cardiovascular Events During Antihypertensive Treatment: Losartan Intervention for Endpoint Reduction in Hypertension Trial

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study

Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Cardiac biochemical markers after cardioversion of atrial fibrillation or atrial flutter

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study

How smoking affects blood pressure

Reproducibility of salt sensitivity testing using a dietary approach in essential hypertension

Reducing Microalbuminuria-Does It Lower Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005

Lowering Albuminuria-Does It Lower the Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005

Magnetic resonance imaging and cine computerized tomography as future tools for cardiac output measurement

Suchergebnisse filtern